突破性治疗指定-话题@MedSci

#突破性治疗指定#

5篇内容 | 977人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1677168, encodeId=f5e416e7168e2, content=<a href='/topic/show?id=8003e5536a9' target=_blank style='color:#2F92EE;'>#突破性治疗指定#</a>, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=68, createdTime=2021-04-04, rootId=0, userName=budeshao, userId=702a27449248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677167, encodeId=91ac16e7167de, content=<a href='/topic/show?id=8003e5536a9' target=_blank style='color:#2F92EE;'>#突破性治疗指定#</a>, objectTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, objectType=article, longId=181137, objectId=82d718113e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d718113e9c, replyNumber=0, likeNumber=73, createdTime=2020-02-01, rootId=0, userName=budeshao, userId=702a27449248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d718113e9c, moduleTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d718113e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677164, encodeId=788416e71641c, content=<a href='/topic/show?id=8003e5536a9' target=_blank style='color:#2F92EE;'>#突破性治疗指定#</a>, objectTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, objectType=article, longId=161117, objectId=2dcd16111ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dcd16111ee7, replyNumber=0, likeNumber=67, createdTime=2019-11-06, rootId=0, userName=budeshao, userId=702a27449248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dcd16111ee7, moduleTitle=美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dcd16111ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677166, encodeId=a69216e716618, content=<a href='/topic/show?id=8003e5536a9' target=_blank style='color:#2F92EE;'>#突破性治疗指定#</a>, objectTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, objectType=article, longId=179673, objectId=1fca1e96732d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca1e96732d, replyNumber=0, likeNumber=68, createdTime=2019-09-26, rootId=0, userName=budeshao, userId=702a27449248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca1e96732d, moduleTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca1e96732d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677165, encodeId=60d216e7165ef, content=<a href='/topic/show?id=8003e5536a9' target=_blank style='color:#2F92EE;'>#突破性治疗指定#</a>, objectTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, objectType=article, longId=167490, objectId=8d7f16e4907c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7f16e4907c, replyNumber=0, likeNumber=53, createdTime=2019-09-30, rootId=0, userName=budeshao, userId=702a27449248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7f16e4907c, moduleTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7f16e4907c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性治疗指定

2020-05-29

budeshao (审核中...)

前往app查看评论内容

#突破性治疗指定#

罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定

2021-04-04

budeshao (审核中...)

前往app查看评论内容

#突破性治疗指定#

勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定

2020-02-01

budeshao (审核中...)

前往app查看评论内容

#突破性治疗指定#

美国FDA向Amicus的AT-GAA治疗迟发型庞贝氏病授予了突破性治疗指定

2019-11-06

budeshao (审核中...)

前往app查看评论内容

#突破性治疗指定#

FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定

2019-09-26

budeshao (审核中...)

前往app查看评论内容

#突破性治疗指定#

拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定

2019-09-30

科室
- - 订阅+
  - 更多科室
工具
服务